JP2004507543A5 - - Google Patents

Download PDF

Info

Publication number
JP2004507543A5
JP2004507543A5 JP2002523898A JP2002523898A JP2004507543A5 JP 2004507543 A5 JP2004507543 A5 JP 2004507543A5 JP 2002523898 A JP2002523898 A JP 2002523898A JP 2002523898 A JP2002523898 A JP 2002523898A JP 2004507543 A5 JP2004507543 A5 JP 2004507543A5
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002523898A
Other languages
English (en)
Japanese (ja)
Other versions
JP4341949B2 (ja
JP2004507543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/041942 external-priority patent/WO2002018383A2/en
Publication of JP2004507543A publication Critical patent/JP2004507543A/ja
Publication of JP2004507543A5 publication Critical patent/JP2004507543A5/ja
Application granted granted Critical
Publication of JP4341949B2 publication Critical patent/JP4341949B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002523898A 2000-09-01 2001-08-30 アザ複素環式誘導体およびその治療的使用 Expired - Fee Related JP4341949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23182900P 2000-09-01 2000-09-01
PCT/US2001/041942 WO2002018383A2 (en) 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007131084A Division JP2007217427A (ja) 2000-09-01 2007-05-16 アザ複素環式誘導体およびその治療的使用

Publications (3)

Publication Number Publication Date
JP2004507543A JP2004507543A (ja) 2004-03-11
JP2004507543A5 true JP2004507543A5 (OSRAM) 2005-03-17
JP4341949B2 JP4341949B2 (ja) 2009-10-14

Family

ID=22870779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002523898A Expired - Fee Related JP4341949B2 (ja) 2000-09-01 2001-08-30 アザ複素環式誘導体およびその治療的使用
JP2007131084A Pending JP2007217427A (ja) 2000-09-01 2007-05-16 アザ複素環式誘導体およびその治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007131084A Pending JP2007217427A (ja) 2000-09-01 2007-05-16 アザ複素環式誘導体およびその治療的使用

Country Status (9)

Country Link
US (4) US6756383B2 (OSRAM)
EP (1) EP1313734B1 (OSRAM)
JP (2) JP4341949B2 (OSRAM)
AT (1) ATE448226T1 (OSRAM)
AU (1) AU2001293233A1 (OSRAM)
DE (1) DE60140456D1 (OSRAM)
ES (1) ES2334641T3 (OSRAM)
PT (1) PT1313734E (OSRAM)
WO (1) WO2002018383A2 (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
JP4361727B2 (ja) * 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CN100526312C (zh) * 2002-08-23 2009-08-12 诺华疫苗和诊断公司 苯并咪唑喹啉酮及其应用
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
WO2004030620A2 (en) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
CA2501932C (en) * 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
WO2004063151A2 (en) * 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
US7329678B2 (en) * 2003-01-28 2008-02-12 Smithkline Beecham Corporation Chemical compounds
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
TWI347940B (en) * 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
US20060183750A1 (en) * 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
WO2006124413A2 (en) * 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
AU2006247062A1 (en) 2005-05-17 2006-11-23 Novartis Ag Methods for synthesizing heterocyclic compounds
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP1909564A4 (en) 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ567979A (en) 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0619370A2 (pt) 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
EP2546359A1 (en) 2005-12-08 2013-01-16 Novartis AG Effects of inhibitors of FGFR3 on gene transcription
BR122019013216B8 (pt) 2006-01-27 2021-07-27 Seqirus Uk Ltd ensaio imunológico para análise de uma vacina contra influenza
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
ES2662716T3 (es) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Inmunógenos conservados de Escherichia coli
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
SI2464658T1 (sl) 2009-07-16 2015-02-27 Novartis Ag Detoksificirani imunogeni escherichie coli
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051212A1 (de) * 2009-10-28 2011-05-05 Basf Se Verwendung heteroaromatischer verbindungen als herbizide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP4144368B1 (en) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
AU2012267556B9 (en) * 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
ES2872555T3 (es) * 2015-06-25 2021-11-02 Univ Health Network Inhibidores de HPK1 y métodos de uso de los mismos
CN107935858B (zh) * 2016-10-12 2020-09-08 利尔化学股份有限公司 5-氟-2-硝基苯酚的制备方法
CN111655690B (zh) * 2017-11-24 2023-01-10 詹森药业有限公司 吡唑并吡啶酮化合物
MA51221A (fr) * 2017-11-24 2020-10-07 Janssen Pharmaceutica Nv Composés de pyrazolopyridinone
CN113227100B (zh) 2018-12-26 2023-05-05 詹森药业有限公司 噻吩并吡啶酮化合物
MX2022012812A (es) * 2020-04-13 2023-01-30 Univ Health Network Métodos para tratar el síndrome de liberación de citocinas.
WO2022188823A1 (zh) * 2021-03-10 2022-09-15 山东轩竹医药科技有限公司 三并环类hpk1抑制剂及其用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE290153C (OSRAM)
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
DE3634066A1 (de) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3739366A1 (de) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
WO1995018801A1 (en) 1994-01-08 1995-07-13 Rhone-Poulenc Agriculture Ltd. Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP2000506880A (ja) 1996-03-15 2000-06-06 ゼネカ・リミテッド シンノリン誘導体及びその使用
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
NZ505921A (en) 1998-03-31 2003-08-29 Warner Lambert Co 1-[5-(2,6-Dimethylpiperidino)pentyl] substituted quinolone serine protease inhibitors and their use for treating thrombin related disorders
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF THE ACTIVITY OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
EP1109555A4 (en) * 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (ko) 1999-03-31 2003-02-25 주식회사 엘지화학 새로운 큐마린계 착물 및 이를 이용한 유기 발광 소자
CZ303660B6 (cs) 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
KR100681724B1 (ko) 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
JP2003512353A (ja) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
CN1307303C (zh) 2000-01-19 2007-03-28 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
JP4341949B2 (ja) * 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
WO2004030620A2 (en) 2002-09-30 2004-04-15 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US6774327B1 (en) * 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
WO2005054183A2 (en) 2003-12-01 2005-06-16 The Scripps Research Institute Quinolinone based protein kinase inhibitors
US20060183750A1 (en) 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors

Similar Documents

Publication Publication Date Title
JP2007191486A5 (OSRAM)
JP2005527587A5 (OSRAM)
JP2007522098A5 (OSRAM)
JP2001526218A5 (OSRAM)
JP2004534774A5 (OSRAM)
JP2003519130A5 (OSRAM)
RU2002107975A (ru) Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения
JP2003535828A5 (OSRAM)
JP2002539181A5 (OSRAM)
JP2002536329A5 (OSRAM)
RU95117068A (ru) Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений
RU2013130256A (ru) Новые циклоспориновые производные для лечения и предупреждения вирусных инфекций
RU93004675A (ru) 1,2,4-оксадиазолил-феноксиалкилизоксазолы, их применение в качестве противовирусных агентов, фармацевтическая композиция
JP2014500265A5 (OSRAM)
RU2000123169A (ru) Бензотиадиазолы и их производные
JP2002515500A5 (OSRAM)
SI20876B (sl) Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje
RU2001135802A (ru) Антагонисты рецептора брадикинина
JP2005527521A5 (OSRAM)
RU2004119963A (ru) Ингибиторы вич интегразы
RU2003127392A (ru) Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
RU97106097A (ru) Производные 2-амино-1,2,3,4-тетрагидро-нафталина, обладающие активностью в отношении сердечно-сосудистой системы
KR970705989A (ko) 심장혈관계에 대해 활성인 2-아미노-1, 2, 3, 4-테트라히드로-나프탈렌의 유도체(derivatives of 2-amino-1, 2, 3, 4-tetrahydro-naphthalene active on the cardiovascular system)
KR890001988A (ko) 치환된 알켄카복실산아미드 및 이의유도체
RU96103685A (ru) 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция